Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Abstract:

:Appropriate and successful management of pain with opioid analgesics is based on tailoring pharmacologic treatment to the individual and identifying the minimal effective dose at which pain is controlled with minimal adverse effects. Morphine and morphine-like-agonists exhibit similar pharmacodynamic profiles, but substantially different receptor affinities and pharmacokinetic properties, which dictate the dosage, route and regimen required to achieve analgesic effect. Opioids exhibit differences in drug elimination resulting in marked variations in the plasma half-life value. Although fentanyl is more potent than morphine, with a shorter duration of action than parenteral morphine, its oral bioavailability is poor and it is administered transdermally. Morphine, with a short half-life and a time to steady-state plasma concentrations of 10-12 hours is better suited than transdermal fentanyl for initial opioid therapy and for the treatment of unstable pain, which requires a fluctuating opioid dose. International guidelines recommend normal-release morphine for initial optimization of individual dose because its pharmacokinetics allow 'real-time' dose regimen changes and rapid identification of the dose required for pain control. Once an effective normal-release morphine dosage is achieved, other administration routes, formulations and opioids can be considered as required. Despite guidelines advocating that transdermal fentanyl should only be used in patients who are shown to be tolerant to strong opioid therapy, in Italy and other European countries, controlled-release or transdermal opioids are often used when starting opioid therapy. Opioids are associated with a wide range of adverse reactions, but these can be minimized with careful drug titration and maintenance. A major challenge with pain control is polypharmacy and the risk of pharmacokinetic or pharmacodynamic drug-drug interactions. Prevention and management of interactions rely on careful and timely adjustment of drug regimens involved, according to the severity of the effect. Dose titration is the key to successful therapy initiation with strong opioids in patients with moderate-to-severe pain. It is the only way to establish the optimal and minimal effective dose and provides the best protection against adverse effects. Committed physicians should adhere to guidelines on the appropriate use of opioids in all patients, particularly those with a high risk of adverse reactions.

journal_name

Clin Drug Investig

authors

Geppetti P,Benemei S

doi

10.2165/0044011-200929001-00002

subject

Has Abstract

pub_date

2009-01-01 00:00:00

pages

3-16

eissn

1173-2563

issn

1179-1918

pii

2912

journal_volume

29 Suppl 1

pub_type

杂志文章,评审
  • Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.

    abstract:BACKGROUND AND OBJECTIVE:There is a risk that disturbances of activities of daily living (ADL) due to rheumatoid arthritis (RA) are increased by the occurrence of fractures, including vertebral compression fractures and femoral neck fractures, in RA patients receiving oral corticosteroid therapy. Bisphosphonates are mo...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/00044011-200828030-00002

    authors: Katayama K,Matsuno T

    更新日期:2008-01-01 00:00:00

  • Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland.

    abstract:BACKGROUND:Overactive bladder is a prevalent condition worldwide that is associated with a considerable burden, both on the patient and on society. OBJECTIVE:Our objective was to assess the economic value of fesoterodine compared with tolterodine extended release (ER) for the treatment of overactive bladder (OAB) with...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-014-0178-1

    authors: Angulo JC,Valpas A,Rejas J,Linden K,Kvasz M,Snedecor SJ

    更新日期:2014-05-01 00:00:00

  • Cycle control and bleeding pattern of a 24/4 regimen of drospirenone 3 mg/ethinylestradiol 20 μg compared with a 21/7 regimen of desogestrel 150 μg/ethinylestradiol 20 μg: a pooled analysis.

    abstract:BACKGROUND AND OBJECTIVE:The degree of cycle control achieved with a hormonal contraceptive method is an important determinant of its acceptance and continuation. This study set out to compare the cycle control and bleeding profile of drospirenone (DRSP) 3 mg/ethinylestradiol (EE) 20 μg in a 24-active pill/4-inert pill...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,meta分析,多中心研究

    doi:10.2165/11590260-000000000-00000

    authors: Anttila L,Neunteufel W,Petraglia F,Marr J,Kunz M

    更新日期:2011-01-01 00:00:00

  • Acetazolamide as Add-on Diuretic Therapy in Exacerbations of Chronic Heart Failure: a Pilot Study.

    abstract:BACKGROUND:Congestion is the main cause of morbidity in patients with heart failure. Treatment of fluid overload is often challenging in everyday clinical practice. OBJECTIVE:The aim of this study was to determine the diuretic effect of acetazolamide in patients with exacerbations of chronic heart failure, in addition...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-017-0577-1

    authors: Imiela T,Budaj A

    更新日期:2017-12-01 00:00:00

  • Manidipine for hypertension not controlled by dual therapy in patients with diabetes mellitus: a non-comparative, open-label study.

    abstract:BACKGROUND AND OBJECTIVE:Little is known about the effects of the calcium channel antagonist manidipine when it is added as a third drug in non-controlled hypertensive patients with diabetes mellitus receiving dual antihypertensive therapy. The aim of this study was to evaluate the response in terms of blood pressure (...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章

    doi:10.2165/11587400-000000000-00000

    authors: Martell-Claros N,de la Cruz JJ

    更新日期:2011-01-01 00:00:00

  • Pharmacokinetics of Repeated Melatonin Drug Administrations Prior to and After Surgery.

    abstract:BACKGROUND:Recent clinical studies have documented the analgesic, anti-inflammatory, antioxidative and anxiolytic effects of exogenous melatonin. The pharmacokinetic properties of melatonin have primarily been investigated in experimental studies. OBJECTIVE:The aim of this study was to estimate the pharmacokinetics of...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-016-0452-5

    authors: Harpsøe NG,Andersen LP,Mielke LV,Jønsson B,Jenstrup MT,Gögenur I,Rosenberg J

    更新日期:2016-12-01 00:00:00

  • Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.

    abstract:BACKGROUND AND OBJECTIVE:The enigmatic etiology of neurodegenerative diseases poses a challenge for the development of novel and efficient drugs. The objective of the present study was to evaluate the efficacy of a polyherbal (test) formulation on cognitive functions, inflammatory markers and oxidative stress in health...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-014-0235-9

    authors: Sadhu A,Upadhyay P,Agrawal A,Ilango K,Karmakar D,Singh GP,Dubey GP

    更新日期:2014-12-01 00:00:00

  • Weekly oral alendronic Acid in male osteoporosis.

    abstract:OBJECTIVE:To evaluate the efficacy and tolerability of alendronic acid 70mg once weekly for the treatment of male osteoporosis. PATIENTS AND METHODS:This randomised, double-blind, placebo-controlled, 12-month trial compared the effect of alendronic acid 70mg once weekly or placebo (randomised 2 : 1) on bone mineral de...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424060-00003

    authors: Miller PD,Schnitzer T,Emkey R,Orwoll E,Rosen C,Ettinger M,Vandormael K,Daifotis A

    更新日期:2004-01-01 00:00:00

  • Topical Lomefloxacin versus Topical Chloramphenicol in the Treatment of Acute Bacterial Conjunctivitis.

    abstract::We performed a prospective, randomised, investigator-masked and parallel-group study to compare topical lomefloxacin 0.3% instilled twice daily with topical chloramphenicol instilled five times daily in the treatment of acute bacterial conjunctivitis. 191 patients (lomefloxacin 96, chloramphenicol 95) were enrolled in...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815040-00001

    authors: Agius-Fernandez A,Patterson A,Fsadni M,Jauch A,Raj PS

    更新日期:1998-01-01 00:00:00

  • Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

    abstract:OBJECTIVE:Weight gain during insulin therapy can be a challenging problem in already overweight type 2 diabetes mellitus patients, affecting treatment compliance and long-term prognosis. The analogue insulin detemir has been reported to have a weight-sparing effect compared with other basal insulins. This pooled analys...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200727040-00007

    authors: Raslová K,Tamer SC,Clauson P,Karl D

    更新日期:2007-01-01 00:00:00

  • Iobitridol: a review of its use as a contrast medium in diagnostic imaging.

    abstract::Iobitridol is a water-soluble, non-ionic, monomeric, low-osmolar, iodine-based contrast medium in which the potential for interaction with membrane proteins in the body has been minimized by stable masking of the molecule's lipophilic tri-iodinated benzene ring. It is approved in various countries worldwide for use as...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-013-0055-3

    authors: McCormack PL

    更新日期:2013-02-01 00:00:00

  • Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece.

    abstract:OBJECTIVE:The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s40261-017-0586-0

    authors: Tzanetakos C,Bargiota A,Kourlaba G,Gourzoulidis G,Maniadakis N

    更新日期:2018-01-01 00:00:00

  • First-in-Man Safety, Tolerability, and Pharmacokinetics of a Novel and Highly Selective Inhibitor of Matrix Metalloproteinase-12, FP-025: Results from Two Randomized Studies in Healthy Subjects.

    abstract:BACKGROUND AND OBJECTIVES:Matrix metalloproteinases (MMPs) are proteases with different biological and pathological activities, and many have been linked to several diseases. Targeting individual MMPs may offer a safer therapeutic potential for several diseases. We assessed the safety, tolerability, and pharmacokinetic...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00981-9

    authors: Abd-Elaziz K,Voors-Pette C,Wang KL,Pan S,Lee Y,Mao J,Li Y,Chien B,Lau D,Diamant Z

    更新日期:2021-01-01 00:00:00

  • Opioid Use and Pain Control in the Elderly After Elective or Urgent Orthopaedic Surgery: A Retrospective Cohort Study.

    abstract:BACKGROUND:As an increasing number of elderly are undergoing orthopaedic procedures, it is important to understand and evaluate postoperative pain management in this population, especially in regard to opioid use. Data in the literature pertaining to the very elderly remains scarce. OBJECTIVES:This study was conducted...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-018-00744-7

    authors: Dagenais-Beaulé V,Tourigny JF,Papillon-Ferland L

    更新日期:2019-03-01 00:00:00

  • Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women.

    abstract:OBJECTIVE:To characterise the pharmacokinetics of indinavir during different phases of the menstrual cycle in HIV-infected women. DESIGN:Open-label study. SETTING:The immunodeficiency clinic at Erie County Medical Center, Buffalo, New York. PATIENTS:Ten HIV-infected women were enrolled in the study. Eligibility crit...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200222020-00007

    authors: Frost CE,Adams J,Shelton M,Ebid AH,Gugino LJ,Hewitt R,Difrancesco R,Ingalls E,Cousins S,Hu J,Morse GD

    更新日期:2002-01-01 00:00:00

  • US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection.

    abstract::Elbasvir/grazoprevir demonstrated high sustained virologic response rates 12 weeks after the end of treatment (SVR12) across five clinical trials in subjects infected with chronic hepatitis C virus (HCV) genotype 1, including those with advanced chronic kidney disease (CKD), and GT4. Despite favorable results overall,...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-017-0492-5

    authors: Boyd SD,Tracy L,Komatsu TE,Harrington PR,Viswanathan P,Murray J,Sherwat A

    更新日期:2017-04-01 00:00:00

  • The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus: Rationale and Design of RosCal Study.

    abstract:INTRODUCTION:More and more evidence suggests that the density of calcification plays an important role in the plaque stability. However, few studies have investigated the statin treatment on the density of plaque calcification in patients with both coronary artery disease (CAD) and type 2 diabetes mellitus. METHODS:On...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章

    doi:10.1007/s40261-016-0445-4

    authors: Zhang W,Luan Y,Jin C,Xu S,Bi X,Zhao Y,Qiu F,Fu G,Wang M

    更新日期:2016-12-01 00:00:00

  • Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.

    abstract:OBJECTIVE:To evaluate the efficacy and safety of the natural platelet-activating factor receptor antagonist, BN 52021 (ginkgolide B) in the treatment of patients with severe sepsis related to Gram-negative and mixed bacterial infection. DESIGN AND SETTING:Prospective, randomised, double-blind, placebo-controlled, mult...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200424030-00002

    authors: Albrecht DM,van Ackern K,Bender HJ,Hof H,Kox W,Victor N,Funk P,Kieser M,Köhler S,Krausch D,Marzi I,Menges T,Schmidt H

    更新日期:2004-01-01 00:00:00

  • Facial Paralysis Following Influenza Vaccination: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System Database.

    abstract:BACKGROUND AND OBJECTIVE:Several cases of facial paralysis have been reported following influenza vaccination; however, recent surveillance studies have not shown an increased risk. In this study, we analyzed the vaccine adverse event reporting system (VAERS) data to determine whether the facial paralysis reporting rat...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00952-0

    authors: Kamath A,Maity N,Nayak MA

    更新日期:2020-09-01 00:00:00

  • Diclofenac epolamine (Flector) patch: evidence for topical activity.

    abstract::This review focuses on previously unpublished clinical and pharmacokinetic data with the diclofenac epolamine (diclofenac hydroxyethylpyrrolidine) patch supporting the hypothesis of a topical effect of this formulation. Previous studies have shown that 1 or 2 weeks of treatment with diclofenac epolamine provides pain ...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/0044011-200929010-00001

    authors: Petersen B,Rovati S

    更新日期:2009-01-01 00:00:00

  • Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and Whole Virus or Split Vaccines: A Review and Meta-Analysis of the Literature.

    abstract::Currently three different inactivated influenza vaccine types are available: whole virus (WV), split (SPL) and subunit (SU) vaccines. Physicians and patients at risk for influenza complications may wonder whether there are important differences between the vaccine types with respect to antibody induction (serology) an...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199815010-00001

    authors: Beyer WE,Palache AM,Osterhaus AD

    更新日期:1998-01-01 00:00:00

  • Sodium oxybate: a review of its use in alcohol withdrawal syndrome and in the maintenance of abstinence in alcohol dependence.

    abstract::A liquid formulation of sodium oxybate (Alcover(®)), the sodium salt of γ-hydroxybutyric acid (GHB), is approved in Italy and Austria for use in alcohol withdrawal syndrome and for the maintenance of abstinence in alcohol dependence. This article reviews the efficacy and tolerability of sodium oxybate in alcohol withd...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.1007/s40261-013-0158-x

    authors: Keating GM

    更新日期:2014-01-01 00:00:00

  • Massive thrombosis of brachiocephalic veins and superior vena cava syndrome in a patient with non-small cell lung cancer treated with the epidermal growth factor receptor inhibitor erlotinib.

    abstract::The superior vena cava (SVC) syndrome occurs when obstruction of this vessel interrupts venous return of blood from the head, upper extremities and thorax to the right atrium. Most cases of SVC syndrome result from neoplasia, especially from lung cancer, but other non-cancer-associated causes may include fibrosis caus...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-200727070-00007

    authors: Salmi R,Gaudenzi P,Di Todaro F,Morandi P,Nielsen I,Manfredini R

    更新日期:2007-01-01 00:00:00

  • Quinapril for treatment of hypertension in Turkey: dose titration and diuretic combination treatment strategies.

    abstract:BACKGROUND AND OBJECTIVE:Recently the PatenT (Prevalence, awareness, treatment and control of hypertension in Turkey) study showed that while the prevalence of hypertension in Turkey is high, effective control of BP is infrequently achieved. This study investigated the efficacy and safety of quinapril (as monotherapy o...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.2165/00044011-200727090-00003

    authors: Yener G,Aran S,Bahceci M,Ozdemir K,Gultekin F,Lowe W

    更新日期:2007-01-01 00:00:00

  • Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.

    abstract:OBJECTIVE:Addressing the needs of migraineurs by actively seeking patient feedback on disease-related disability and treatment satisfaction may lead to improved management and treatment outcomes. Patient feedback can be collected in postmarketing surveillance (PMS) studies. The objective of this PMS study was to evalua...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200727010-00005

    authors: Diener HC,Evers S

    更新日期:2007-01-01 00:00:00

  • Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.

    abstract:BACKGROUND AND OBJECTIVES:As compared with individual tablets, saxagliptin/metformin extended-release (XR) fixed-dose combination (FDC) tablets offer potential for increased patient compliance with the convenience of once-daily dosing. Two bioequivalence studies assessed the fed-state bioequivalence of saxagliptin/metf...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,随机对照试验

    doi:10.2165/11590290-000000000-00000

    authors: Boulton DW,Smith CH,Li L,Huang J,Tang A,LaCreta FP

    更新日期:2011-01-01 00:00:00

  • Barriers to pain management: focus on opioid therapy.

    abstract::Despite the availability of effective pain treatments, there are numerous barriers to effective management resulting in a large proportion of patients not achieving optimal pain control. Chronic pain is inadequately treated because of a combination of cultural, societal, educational, political and religious constraint...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章,评审

    doi:10.2165/11630040-000000000-00000

    authors: Zuccaro SM,Vellucci R,Sarzi-Puttini P,Cherubino P,Labianca R,Fornasari D

    更新日期:2012-02-22 00:00:00

  • Observational Safety Study of Clottafact® Fibrinogen Concentrate: Real-World Data in Mexico.

    abstract:BACKGROUND AND OBJECTIVE:The use of fibrinogen concentrate to treat or prevent major bleeding with regard to potential adverse reactions has not been free of controversy. Our objective was to perform a post-authorization safety study to describe the use of Clottafact® (LFB Biomedicaments) fibrinogen concentrate in real...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.1007/s40261-020-00906-6

    authors: Colin-Bracamontes I,Pérez-Calatayud ÁA,Carrillo-Esper R,Rodríguez-Ayala E,Padilla-Molina M,Posadas-Nava A,Olvera-Vázquez S,Hernández-Salgado L

    更新日期:2020-05-01 00:00:00

  • Oxycodone controlled-release as first-choice therapy for moderate-to-severe cancer pain in Italian patients: results of an open-label, multicentre, observational study.

    abstract:BACKGROUND AND OBJECTIVES:Cancer pain affects patients at all stages of the disease and there are clear guidelines for its management. Morphine is considered the first-choice strong opioid in the treatment of moderate-to-severe pain; however, numerous studies have shown that oxycodone controlled-release (CR) has a simi...

    journal_title:Clinical drug investigation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.2165/00044011-200828070-00001

    authors: Silvestri B,Bandieri E,Del Prete S,Ianniello GP,Micheletto G,Dambrosio M,Sabbatini G,Endrizzi L,Marra A,Aitini E,Calorio A,Garetto F,Nastasi G,Piantedosi F,Sidoti V,Spanu P

    更新日期:2008-01-01 00:00:00

  • Salmeterol/Fluticasone combination inhaler: a new, effective and well tolerated treatment for asthma.

    abstract:OBJECTIVE:The efficacy and tolerability of a new combination inhaler containing both salmeterol 50mg and fluticasone 100mg in a single device was compared with the delivery of the two drugs via two separate inhalers in a multicentre, double-blind, double-dummy study. PATIENTS:244 symptomatic asthma patients (age range...

    journal_title:Clinical drug investigation

    pub_type: 杂志文章

    doi:10.2165/00044011-199816030-00003

    authors: Bateman ED,Britton M,Carrillo J,Almeida J,Wixon C

    更新日期:1998-01-01 00:00:00